Cogstate (CGS) Stock Overview
A neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CGS passed our risk checks.
CGS Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Cogstate Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.43 |
| 52 Week High | AU$2.37 |
| 52 Week Low | AU$0.86 |
| Beta | -0.36 |
| 1 Month Change | 41.28% |
| 3 Month Change | 43.79% |
| 1 Year Change | 161.29% |
| 3 Year Change | 16.27% |
| 5 Year Change | 247.14% |
| Change since IPO | 386.00% |
Recent News & Updates
Recent updates
Earnings Not Telling The Story For Cogstate Limited (ASX:CGS) After Shares Rise 27%
Sep 26
Cogstate (ASX:CGS) Is Very Good At Capital Allocation
Aug 05Cogstate Limited's (ASX:CGS) 31% Price Boost Is Out Of Tune With Earnings
Jul 18Cogstate Limited Beat Revenue Forecasts By 9.5%: Here's What Analysts Are Forecasting Next
Feb 21
Reacquisition Of Eisai IP Will Unlock New Markets For Clinical Trials
Diversification into new indications and reacquisition of IP expand market opportunities, enhance revenue potential, and reduce dependency on single areas.Cogstate Limited (ASX:CGS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Dec 14Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now
Aug 30There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital
Jul 26If EPS Growth Is Important To You, Cogstate (ASX:CGS) Presents An Opportunity
May 13The Price Is Right For Cogstate Limited (ASX:CGS)
Jan 17Is Cogstate Limited (ASX:CGS) Trading At A 29% Discount?
Jul 26Returns Are Gaining Momentum At Cogstate (ASX:CGS)
Apr 14Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%
Mar 23Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts
Mar 02Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate
Jan 13Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%
Oct 04Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?
Sep 28Returns On Capital Are A Standout For Cogstate (ASX:CGS)
Sep 02We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease
Jun 30Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital
Mar 22We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation
Oct 20Cogstate (ASX:CGS) Is Looking To Continue Growing Its Returns On Capital
Jul 23Is Cogstate (ASX:CGS) Using Too Much Debt?
Apr 29Shareholder Returns
| CGS | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | 11.0% | 1.7% | 1.5% |
| 1Y | 161.3% | 69.8% | 9.2% |
Return vs Industry: CGS exceeded the Australian Healthcare Services industry which returned 69.8% over the past year.
Return vs Market: CGS exceeded the Australian Market which returned 9.2% over the past year.
Price Volatility
| CGS volatility | |
|---|---|
| CGS Average Weekly Movement | 6.3% |
| Healthcare Services Industry Average Movement | 8.3% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in AU Market | 19.8% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: CGS has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CGS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 148 | Brad O'Connor | www.cogstate.com |
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. It offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer’s disease and dementia, preclinical Alzheimer’s disease, pediatrics and rare disease, Parkinson’s disease, multiple sclerosis, schizophrenia, oncology, safety, and sleep and mood disorders. The company also designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments.
Cogstate Limited Fundamentals Summary
| CGS fundamental statistics | |
|---|---|
| Market cap | AU$398.95m |
| Earnings (TTM) | AU$15.34m |
| Revenue (TTM) | AU$80.31m |
Is CGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGS income statement (TTM) | |
|---|---|
| Revenue | US$53.09m |
| Cost of Revenue | US$20.95m |
| Gross Profit | US$32.14m |
| Other Expenses | US$21.99m |
| Earnings | US$10.14m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.059 |
| Gross Margin | 60.53% |
| Net Profit Margin | 19.11% |
| Debt/Equity Ratio | 0% |
How did CGS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/07 15:24 |
| End of Day Share Price | 2025/10/07 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cogstate Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elyse Shapiro | Canaccord Genuity |
| Dennis Hulme | Taylor Collison Limited |